- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT05882448
Studie av innflytelsen av intraperitoneal insufflasjon av CO2 ved laparoskopi på den kortsiktige utviklingen av premature spedbarn med ulcerøs nekrotiserende enterokolitt (NECO2)
Studie av påvirkningen av intraperitoneal insufflasjon av karbondioksid (CO2) ved laparoskopi på den kortsiktige utviklingen av premature spedbarn med ulcerøs nekrotiserende enterokolitt
Ulcerative-necrotizing enterocolitis (ECUN) is an infectious and inflammatory disease of the digestive tract, which can lead to intestinal necrosis or perforation.
This severe pathology of the newborn , often premature, requires urgent medical and surgical treatment in 25 to 50% of cases. The morbidity is high, both digestive and neurological. ECUN can lead to complications at short-term (death, intestinal stenosis) and at long-term (neuro-cognitive disorders). The challenge of preserving the neurological development is a major issue. It involves control of inflammation. This inflammation causes neurological lesions and is responsible for a disorder of the long-term neurocognitive development.
At Robert-Debré and Trousseau, the management of newborns with ECUN is focused on the control of this inflammation. A laparoscopy is performed first. The carbon dioxide (CO2) insufflated into the abdomen during a laparoscopy is thought to have an anti-inflammatory effect according to several experimental and clinical studies. A preliminary retrospective study at Robert-Debré showed a decrease in postoperative inflammation (decrease in C reactive protein at Day2 and Day 7 post-op) as well as a decrease in morbimortality (decrease in the rate of stoma and reoperation) in children who had a laparoscopic first operation compared to those who had a laparotomy alone. However, in many hospitals, laparotomy alone is currently the only surgical option.
This preliminary study may demonstrate that laparoscopy decreases early morbidity and mortality in children with ECUN through reduced inflammation, as reflected by postoperative C reactive protein.
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
NECO2 is a pilot trial, evaluating the intermediate effectiveness to short/medium term of laparoscopy on the inflammatory reaction of premature newborns with complicated ECUN, requiring surgical treatment.
This is a multicenter randomized controlled trial in single blind, in two parallel arms, in ratio 1:1, of superiority.
This trial compares laparoscopy plus laparotomy versus laparotomy alone.
Children will be randomized into 2 groups:
- Laparoscopy + laparotomy group
- Laparotomy group
The main objective is to evaluate the inflammatory response Day 2 postoperative in preterm infants with ECUN who have undergone surgery.
The main criterion is the evolution of the blood C reactive protein level between Day 0 and Day 2 postoperatively.
The secondary objectives are:To evaluate in premature babies with ECUN who have had a surgical intervention (laparoscopy + laparotomy or laparotomy alone):
A.The postoperative biological inflammatory response at Day 7 B.Post-operative biological inflammatory response from Day 0 to Day 7 C.Post-operative mortality D.Post-operative bowel morbidity E.Post-operative re-intervention rate F.Length of hospital stay G.Post-operative neurological morbidity, medium term (corrected term 41 SA)
- To evaluate the tolerance of laparoscopy :
H.Intraoperative cardiorespiratory I.Loco-regional lesions linked to the insertion of the trocar
Secondary endpoints:
A. C reactive protein blood level at Day 7 B. Blood levels of Procalcitonin, Interleukin 6 and Tumor Necrosis Factor-alpha at Day 1, Day 2, Day 4, Day 7 C. Postoperative death from any cause D. Stoma rate, duration of parenteral nutrition, duration of hemodynamic support, duration of invasive ventilation (High frequency oscillatory ventilation/Synchronized Intermittent Mandatory Ventilation), Post-ECUN intestinal stenosis rate E. Re-intervention (laparotomy) and cause (post-ECUN stenosis, stoma closure) F. Length of hospital stay until return home G. Early postoperative neurological lesions observed on transfontanellar ultrasound and MRI at the corrected term of 41 weeks of amenorrhea, H. Oxygen saturation (SaO2), hypercapnia (pCO2) blood pressure (BP), cerebral oxygenation (Near InfraRed Spectroscopy (NIRS)) intraoperatively I. Intraoperative clinical monitoring: exploration of adjacent organs. Post-operative clinical monitoring: digestive signs monitoring of wounds until discharge.
Group 1: laparotomy only Group 2: laparotomy and laparoscopy
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Louise MONTALVA, Dr
- Telefonnummer: +33 1.71.73.89.97
- E-post: louise.montalva@aphp.fr
Studer Kontakt Backup
- Navn: Arnaud BONNARD, Pr
- Telefonnummer: +33 1 40 03 23 59
- E-post: arnaud.bonnard@aphp.fr
Studiesteder
-
-
-
Paris, Frankrike, 75012
- Rekruttering
- Hôpital Armand Trousseau Service de Chirurgie Pédiatrique et Néonatale
-
Ta kontakt med:
- MONTALVA Louise, Dr
- Telefonnummer: +33 +33 1.71.73.89.97
- E-post: louise.montalva@aphp.fr
-
Paris, Frankrike
- Rekruttering
- Hôpital Robert Debré Service de Chirurgie Pédiatrique
-
Ta kontakt med:
- BONNARD Arnaud, Pr
- Telefonnummer: +33 33 1 40 03 41 21
- E-post: arnaud.bonnard@aphp.fr
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Barn
- Voksen
- Eldre voksen
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Premature newborn (term of birth: <37 weeks of amenorrhea)
- Diagnosis of ECUN by the surgeon (distension abdominal +/- rectal bleeding +/- green gastric residue, increased biological inflammatory syndrome, + pneumatosis on abdominal radiography)
- Hospitalized and complicated ECUN: presenting either a pneumoperitoneum on abdominal X-ray or a absence of clinical and biological improvement after 48 hours of maximum well-conducted medical treatment (IV antibiotic therapy and digestive rest).
- Hospitalized in the 2 participating centers
- Of which the 2 holders of parental authority have been informed and have signed the consent form
- Having social security coverage (social security or CMU)
Exclusion Criteria:
- Instability contraindicating movement to the operating room or contraindicating CO2 insufflation
- Diagnosis of isolated perforation of the small intestine (radiography:
pneumoperitoneum without pneumatosis)
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Dobbelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Aktiv komparator: Laparotomy
Exploratory and therapeutic laparotomy if necessary, in case of necrotic intestine requiring resection with anastomosis or stoma-type bowel diversion |
Exploratory and therapeutic laparotomy if necessary, in case of necrotic intestine requiring resection with anastomosis or stoma-type bowel diversion |
|
Eksperimentell: Laparotomy and laparoscopy
Exploratory and therapeutic laparotomy if necessary preceded by laparoscopy with insufflation of CO2 (placement of a 3mm trocar in the left hypochondrium and insufflation of a pneumoperitoneum (carbon dioxide, pressure: 6 mmHg, flow rate: 1.5 Liter/minute) for a duration of at least 5 minutes. |
Exploratory and therapeutic laparotomy if necessary, in case of necrotic intestine requiring resection with anastomosis or stoma-type bowel diversion laparoscopy with insufflation of CO2 (placement of a 3mm trocar in the left hypochondrium and insufflation of a pneumoperitoneum (carbon dioxide, pressure: 6 mmHg, flow rate: 1.5 Liter/minute) for a duration of at least 5 minutes. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
C reactive protein blood level
Tidsramme: between Day 0 and Day 2 post surgery
|
C reactive protein blood level |
between Day 0 and Day 2 post surgery
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Postoperative biological inflammatory reaction
Tidsramme: Day 7 post surgery
|
C reactive protein blood level |
Day 7 post surgery
|
|
Specific post-operative biological inflammatory reaction
Tidsramme: Day1, day 2, day 4 and day 7 post surgery
|
Procalcitonin, Interleukin 6 and Tumor Necrosis Factor-alpha blood level |
Day1, day 2, day 4 and day 7 post surgery
|
|
Postoperative mortality
Tidsramme: up to 3 months
|
Death due to any postoperative cause |
up to 3 months
|
|
Postoperative intestinal morbidity: stoma rate
Tidsramme: up to 3 months
|
Stoma rate |
up to 3 months
|
|
Postoperative intestinal morbidity: Duration of parenteral nutrition
Tidsramme: up to 3 months
|
Duration of parenteral nutrition |
up to 3 months
|
|
Postoperative intestinal morbidity: Duration of hemodynamic support
Tidsramme: up to 3 months
|
Duration of hemodynamic support |
up to 3 months
|
|
Postoperative intestinal morbidity: Duration of invasive ventilation (HFO: High frequency oscillatory ventilation/VACI: Synchronized Intermittent Mandatory Ventilation)
Tidsramme: up to 3 months
|
Duration of invasive ventilation (HFO: High frequency oscillatory ventilation/VACI: Synchronized Intermittent Mandatory Ventilation) |
up to 3 months
|
|
Postoperative intestinal morbidity: Rate of intestinal stenosis post-ECUN
Tidsramme: up to 3 months
|
Rate of intestinal stenosis post-ECUN |
up to 3 months
|
|
Postoperative reoperation rate
Tidsramme: up to 3 months
|
Reoperation (laparotomy) and cause (post ECUN stenosis, stoma closure) |
up to 3 months
|
|
Length of hospitalization
Tidsramme: up to 3 months
|
Duration of hospitalization until return home |
up to 3 months
|
|
Medium-term postoperative neurological morbidity
Tidsramme: up to 3 months
|
Early postoperative neurological lesions observed on transfontanellar ultrasound and MRI at term corrected for 41 weeks of amenorrhea |
up to 3 months
|
|
Oxygen saturation (SaO2) (Tolerance of laparoscopy (Intraoperative cardio-respiratory))
Tidsramme: During Surgery
|
Oxygen saturation (SaO2) |
During Surgery
|
|
Hypercapnia (pCO2) (Tolerance of laparoscopy (Intraoperative cardio-respiratory))
Tidsramme: During Surgery
|
hypercapnia (pCO2) |
During Surgery
|
|
Blood pressure (BP) (Tolerance of laparoscopy (Intraoperative cardio-respiratory))
Tidsramme: During Surgery
|
blood pressure (systolic and diastolic) |
During Surgery
|
|
Cerebral oxygenation (Near InfraRed Spectroscopy (NIRS)) (Tolerance of laparoscopy (Intraoperative cardio-respiratory))
Tidsramme: During Surgery
|
cerebral oxygenation (Near InfraRed Spectroscopy (NIRS)) intraoperatively |
During Surgery
|
|
Presence of loco-regional lesions related to the insertion of the trocar (Tolerance of laparoscopy)
Tidsramme: up to 3 months
|
Presence of loco-regional lesions related to the insertion of the trocar |
up to 3 months
|
Samarbeidspartnere og etterforskere
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Urogenitale sykdommer
- Kvinnelige urogenitale sykdommer og graviditetskomplikasjoner
- Tarmsykdommer
- Obstetrisk arbeid, prematur
- Obstetriske arbeidskomplikasjoner
- Graviditetskomplikasjoner
- Sykdommer i fordøyelsessystemet
- Gastrointestinale sykdommer
- Gastroenteritt
- Enterokolitt
- For tidlig fødsel
- Enterokolitt, nekrotiserende
- Diagnostiske teknikker og prosedyrer
- Diagnose
- Kirurgiske prosedyrer, operativ
- Minimalt invasive kirurgiske inngrep
- Diagnostiske teknikker, kirurgisk
- Endoskopi
- Laparoskopi
- Laparotomi
Andre studie-ID-numre
- APHP221170
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .